Skip to main navigation Skip to main content Skip to page footer
Menu

PARKINSON'S & OTHER MOVEMENT DISORDERS

SPECIALIZED OUTPATIENT CLINICS OF PARKINSON’S DISEASE AND RELATED MOVEMENT DISORDERS- AND OF – INTERVENTIONAL MAGAMENT OF PARKINSON’S DISEASE AND OTHER MOVEMENT DISORDERS

EDUCATIONAL-RESEARCH ACTIVITIES

 

The specialized outpatient Clinics that deal with Parkinson’s Disease and related Movement Diosrders, beyond the clinical services that they offer, also boast multidimensional educational and research activities.

Educational activities involve:

  • Education of Neurology residents of the First Department of Neurology in the clinical examination, assessment, investigation and treatment of Movement Disorders. This education occurs first through rotations of the residents through the Specialty Clinics devoted to Movement Disorders. As part of the educational program of the Department there is a monthly Video Presentation based on cases from the Movement Disorders Clinics, while there are also a number of lectures devoted to Movement Disorders throughout the Academic year. Movement disorders are also presented as Case Reports from the Specialty Clinics twice during the Academic year.     
  • Education in Movement Disorders of younger colleagues and residents performing their training in Neurology in Greece through their participation   in many Greek Scientific Meetings and seminars where members of the Movement Disorders division of the First Department of Neurology run teaching courses.  Along these lines, members of the Specialty Clinics in Movement Disorders participate actively in the educational activities of the Movement Disorders Division of the Hellenic Neurological Association (http://www.enee.gr/). 
  • Organization of and participation in International Meetings/Seminars related to Movement Disorders. Indicatively, the Department organized a session on Rare Movement Disorders at the last 2024 Meeting on Rare Neurological Disorders. Members of the Movement Disorders Specialty Clinics participate in many other international meetings which relate to Movement Disorders and in particular Neurodegenerative Diseases.
  • Active participation in the European Network of Rare Neurodegenrative Diseases ERN-RND (https://www.ern-rnd.eu), which offers multiple educational opportunities to younger colleagues.  

 

Research activities of members of the Movement Disorders Specialty Clinics include:

  • Genetic characterization of patients with Parkinson’s Disease, in collaboration with the Neurogenetics Unit, the laboratory of Neurodegenerative Diseases at the Biomedical Research Foundation of the Academy of Athens (BRFAA) (http://www.bioacademy.gr/faculty-details/GMI/lewnidas) and with the Institute of Child Health, as well as with Institutions abroad, such as with the laboratory of Thomas Gasser in  Tubingen, and international consortia such as the GEOPD or GP2.  These studies aim at deciphering the Genetic underpinnings of Parkinson’s Disease in Greece.       
  • Participation in the Study PPMI (Parkinson’s Disease Progression Markers Initiative), sponsored by the Michael J Fox Foundation USA.  This is an international network of study of biological markers in Parkinson’s Disease (http://www.ppmi-info.org/about-ppmi/).  The Center at the University of Athens participates in the study mainly with patients with rare genetic forms, patients with recent disease onset, as well as with subjects with prodromal forms of the disease, such as the Sleep Disorder REM Sleep Behavior Disorder (RBD).  Of special interest is the recent expansion of the study to include members of the community who only manifest hyposmia.
  • Study of Biomarkers in Parkinson’s Disease and atypical Parkinsonian syndromes.  We are studying biomarkers that correspond to mechanisms of pathogenesis in the Central Nervous System.  Currently, we are focusing on the study of markers related to alpha-synuclein, but also indices of lysosomal function, as well as neuronal microRNAs.    Of special interest is a study of the levels of Parkin (PRKN) in rare genetic forms of PD.  These studies are performed in collaboration with the laboratory of Neurodegenerative Diseases at BRFAA (http://www.bioacademy.gr/faculty-details/GMI/lewnidas).   
  • Prospective Study of prodromal forms of Parkinson’s Disease (such as subjects with REM Sleep Behavior Disorder (RBD), or asymptomatic carriers of mutations linked to Parkinson’s Disease).  This study is performed in collaboration with the Neurophysiological Unit of Children and Adults of the Second Department of Neurology, as well as with the laboratory of the study of Thin Nerve Fibers and the Autonomic Nervous System of the First Department of Neurology, and is supported by the Michael J Fox Foundation.
  • Participation in National Networks of Neurodegenerative Diseases, such as currently Brain Precision (https://hub.uoa.gr/nevroekfylistika-nosimata-i-nea-pandimia-einai-edo/)    
  • Clinical and laboratory study (Sonography, triplex, bone density measurements) for the analysis of the symptomatology of dysfunctional and painful shoulder as an early sign of Parkinson’s Disease  (in collaboration with the Second Department of Orthopedics of the UoA Medical School)
  • Neuropsychological study of combinatorial memory for faces-names-demographic features (profession) of patients with Parkinson’s Disease without dementia, through the use of the Face Name Associative Memory Exam (GR-FNAME12), as an early indicator of cognitive decline.
  • Neuropsychological study of the perception of distances and the avoidance of hurdles in patients with Parkinson’s Disease, as part of the investigation of the clinical characteristics of the disease that are related to  freezing of gait.     
  • Study of Psychotic features in early Parkinson’s Disease.  The study is performed in collaboration with the First Department of Psychiatry.
  • Study for the documentation of non-motor symptoms of Parkinson’s Disease, such as depression, sleep disorders, and, especially, impulse control disorders in relation to drug administration and various disease parameters, but also pre-morbid conditions (collaboration with the First Department of Psychiatry).
  • Examination of a possible common pathophysiological basis for cognitive decline in Schizophrenic disorders and Parkinson’s Disease.   The study compares the behavioral and neuroimaging data of patients with Parkinson’s Disease with corresponding data from patients with Schizophrenia, using as reference an elementary sensorimotor decision Center (collaboration with the First Department of Psychiatry).
  • Study of Parkinson’s Disease subtypes, especially those related to age of onset or symmetry
  • Genetic study of generalized and focal Dystonias, as well as other rare Movement Disorders.  These studies are performed in collaboration with Centers abroad, such as the Laboratory of Enza Maria Valente (Santa Lucia Foundation).
  • Creation of pluripotent stem cells from patients with genetic forms of Parkinson’s Disease, in collaboration with the Section of Neurobiology at Pasteur Institute, Athens (https://www.pasteur.gr/el/tomeas-neyrobiologias).

 

Indicative Publications

1. Bozi M, Matarin M, Theocharis I, Potagas C, Stefanis L (2009) A patient with pantothenate kinase-associated neurodegeneration and supranuclear gaze palsy. Clin Neurol Neurosurg. 111(8):688-90

2. Stefanis N, Bozi M, Christodoulou C, Douzenis A, Gasparinatos G, Stamboulis E, Stefanis C, Stefanis L (2010) Isolated delusional syndrome in Parkinson's Disease. Parkinsonism Relat Disord. 16(8):550-2.

3.  Moraitou M, Hadjigeorgiou G, Monopolis I, Dardiotis E, Bozi M, Vassilatis D, Vilageliu L, Grinberg D, Xiromerisiou G, Stefanis L, Michelakakis H (2011) β-Glucocerebrosidase gene mutations in two cohorts of Greek patients with sporadic Parkinson's disease. Mol Genet Metab. 104(1-2):149-52

4. Vekrellis K, Xilouri M, Emmanouilidou E, Rideout HJ, Stefanis L (2011) Pathological roles of α-synuclein in neurological disorders. Lancet Neurol. 10(11):1015-25

5. Argyriou A, Dermentzaki G, Papasilekas T, Moraitou M, Stamboulis E, Vekrellis K, Michelakakis H, Stefanis L (2012) Increased dimerization of alpha-synuclein in erythrocytes in Gaucher disease and aging. Neurosci Lett. 528(2):205-9

6. Michelakakis H, Xiromerisiou G, Dardiotis E, Bozi M, Vassilatis D, Kountra PM, Patramani G, Moraitou M, Papadimitriou D, Stamboulis E, Stefanis L, Zintzaras E, Hadjigeorgiou GM (2012)  Evidence of an association between the scavenger receptor class B member 2 gene and Parkinson's disease.  Mov Disord. 27(3):400-5

7. Liozidou A, Potagas C, Papageorgiou SG, Zalonis I. (2012) The role of working memory and information processing speed on Wisconsin card sorting test performance in Parkinson disease without dementia. J Geriatr Psychiatry Neurol 25(4): 215-21

8. Stamelou M, Christodoulou C, Stefanis L (2013) Dopamine agonists and delusional jealousy in Parkinson's disease: a cross-sectional prevalence study. Mov Disord. 28(5):689 [letter to the editor]

9. Bozi M, Papadimitriou D, Antonellou R, Moraitou M, Maniati M, Vassilatis DK, Papageorgiou SG, Leonardos A, Tagaris G, Malamis G, Theofilopoulos D, Kamakari S, Stamboulis E, Hadjigeorgiou GM, Athanassiadou A, Michelakakis H, Papadimitriou A, Gasser T, Stefanis L (2014) Genetic assessment of familial and early-onset Parkinson's disease in a Greek population. Eur J Neurol 21(7): 963-968

10.  Kara E, Xiromerisiou G, Spanaki C, Bozi M, Koutsis G, Panas M, Dardiotis E, Ralli S, Bras J, Letson C, Edsall C, Pliner H, Arepalli S, Kalinderi K, Fidani L, Bostantjopoulou S, Keller MF, Wood NW, Hardy J, Houlden H, Stefanis L, Plaitakis A, Hernandez D, Hadjigeorgiou GM, Nalls MA, Singleton AB (2014) Assessment of Parkinson's disease risk loci in Greece. Neurobiol Aging. 35(2):442.e9-442

11. Stamelou M, Diehl-Schmid J, Hapfelmeier A, Kontaxopoulou D, Stefanis L, Oertel WH, Bhatia KP, Papageorgiou SG, Höglinger GU. (2015) The frontal assessment battery is not useful to discriminate progressive supranuclear palsy from frontotemporal dementias. Parkinsonism Relat Disord. 21(10):1264-8

12. Papagiannakis N, Xilouri M, Koros C, Stamelou M, Antonelou R, Maniati M, Papadimitriou D, Moraitou M, Michelakakis H, Stefanis L (2015) Lysosomal alterations in peripheral blood mononuclear cells of Parkinson's disease patients. Mov Disord. 30(13):1830-4

13. Ghika A, Kyrozis A, Potagas C, Louis ED. (2015) Motor and non-motor features: Differences between patients with isolated essential tremor and patients with both essential tremor and Parkinson’s disease. Tremor Other Hyperkinet Mov, 5: 335

14. Xilouri M, Brekk OR, Stefanis L (2016) Autophagy and Alpha-Synuclein: Relevance to Parkinson's Disease and Related Synucleopathies. Mov Disord. 31(2):178-92

15. Papadimitriou D, Antonelou R, Miligkos M, Maniati M, Papagiannakis N, Bostantjopoulou S, Leonardos A, Koros C, Simitsi A, Papageorgiou SG, Kapaki E, Alcalay RN, Papadimitriou A, Athanassiadou A, Stamelou M, Stefanis L (2016) Motor and Nonmotor Features of Carriers of the p.A53T Alpha-Synuclein Mutation: A Longitudinal Study. Mov Disord. 31(8):1226-30

16. Pons R, Kekou K, Antonellou R, Svingou M, Kanavakis E, Stefanis L (2016) Analysis of a founder mutation in the TH gene in a cohort of greek patients with Parkinson's disease. Mov Disord. 31(11):1753-1754

17. Bougea A, Koros C, Stamelou M, Simitsi A, Papagiannakis N, Antonelou R, Papadimitriou D, Breza M, Tasios K, Fragkiadaki S, Geronicola Trapali X, Bourbouli M, Koutsis G, Papageorgiou SG, Kapaki E, Paraskevas GP, Stefanis L. (2017) Frontotemporal dementia as the presenting phenotype of p.A53T mutation carriers in the alpha-synuclein gene. Parkinsonism Relat Disord. 35:82-87

18. Kouroupi G, Taoufik E, Vlachos IS, Tsioras K, Antoniou N, Papastefanaki F, Chroni-Tzartou D, Wrasidlo W, Bohl D, Stellas D, Politis PK, Vekrellis K, Papadimitriou D, Stefanis L, Bregestovski P, Hatzigeorgiou AG, Masliah E, Matsas R (2017) Defective synaptic connectivity and axonal neuropathology in a human iPSC-based model of familial Parkinson's disease. Proc Natl Acad Sci U S A. 114(18):E3679-E3688

19. Koros C, Simitsi A, Stefanis L (2017) Genetics of Parkinson's Disease: Genotype-Phenotype Correlations. Int Rev Neurobiol. 132:197-231

20. Darling A, Tello C, Martí MJ, .. Lupo V, Stefanis L, Pons R, Espinós C, Temudo T, Pérez Dueñas B (2017) Clinical rating scale for pantothenate kinase-associated neurodegeneration: A pilot study. Mov Disord. 32(11):1620-1630

21. Papagiannakis N, Koros C, Stamelou M, Simitsi AM, Maniati M, Antonelou R, Papadimitriou D, Dermentzaki G, Moraitou M, Michelakakis H, Stefanis L (2018) Alpha-synuclein dimerization in erythrocytes of patients with genetic and non-genetic forms of Parkinson's Disease. Neurosci Lett. 672:145-149

22. Breza M, Koutsis G, Karadima G, Potagas C, Kartanou C, Papageorgiou SG, Paraskevas GP, Kapaki E, Stefanis L, Panas M (2018) The different faces of the p. A53T alpha-synuclein mutation: A screening of Greek patients with parkinsonism and/or dementia.  Neurosci Lett. 672:136-139

23. Koros C, Stamelou M, Simitsi A, Beratis I, Papadimitriou D, Papagiannakis N, Fragkiadaki S, Kontaxopoulou D, Papageorgiou SG, Stefanis L (2018) Selective cognitive impairment and hyposmia in p.A53T SNCA PD vs typical PD. Neurology 90(10):e864-e869

24. Simitsi A, Koros C, Moraitou M, Papagiannakis N, Antonellou R, Bozi M, Angelopoulou E, Stamelou M, Michelakakis H, Stefanis L (2018) Phenotypic Characteristics in GBA-Associated Parkinson's Disease: A Study in a Greek Population. J Parkinsons Dis. 8(1):101-105

25. Vavougios GD, Doskas T, Kormas C, Krogfelt KA, Zarogiannis SG, Stefanis L (2018) Identification of a prospective early motor progression cluster of Parkinson's disease: Data from the PPMI study. J Neurol Sci. 387:103-108

26. Stamelou M, Petrucci S, Ginevrino M, Pons R, Papagiannakis N, Stefanis L, Valente EM (2018) Intrafamilial variability in a polish family harbouring a frameshift THAP1 mutation. J Neurol Sci. 388:158

27. Koros C, Simitsi A, Prentakis A, Beratis I, Papadimitriou D, Kontaxopoulou D, Fragkiadaki S, Papagiannakis N, Seibyl J, Marek K, Papageorgiou SG, Trapali XG, Stamelou M, Stefanis L. (2018) 123I-FP-CIT SPECT [(123) I-2β-carbomethoxy-3β-(4-iodophenyl)-N-(3-fluoropropyl) nortropane single photon emission computed tomography] Imaging in a p.A53T α-synuclein Parkinson's disease cohort versus Parkinson's disease. Mov Disord. 33(11):1734-1739

28. Elkouris M, Kouroupi G, Vourvoukelis A, Papagiannakis N, Kaltezioti V, Matsas R, Stefanis L, Xilouri M, Politis PK.(2019) Long Non-coding RNAs Associated With Neurodegeneration-Linked Genes Are Reduced in Parkinson's Disease Patients. Front Cell Neurosci. 2019 Feb 22;13:58

29. Wilson H, Dervenoulas G, Pagano G, Koros C, Yousaf T, Picillo M, Polychronis S, Simitsi A, Giordano B, Chappell Z, Corcoran B, Stamelou M, Gunn RN, Pellecchia MT, Rabiner EA, Barone P, Stefanis L, Politis M. (2019) Serotonergic pathology and disease burden in the premotor and motor phase of A53T α-synuclein parkinsonism: a cross-sectional study. Lancet Neurol.18(8):748-759.

30. Angelopoulou E, Bozi M, Simitsi AM, Koros C, Antonelou R, Papagiannakis N, Maniati M, Poula D, Stamelou M, Vassilatis DK, Michalopoulos I, Geronikolou S, Scarmeas N, Stefanis L. (2019) The relationship between environmental factors and different Parkinson's disease subtypes in Greece: Data analysis of the Hellenic Biobank of Parkinson's disease. Parkinsonism Relat Disord. 67:105-112

31. Papagiannakis N, Xilouri M, Koros C, Simitsi AM, Stamelou M, Maniati M, Stefanis L. (2019) Autophagy dysfunction in peripheral blood mononuclear cells of Parkinson's disease patients. Neurosci Lett. 704:112-115

32. Bougea A, Maraki MI, Yannakoulia M, Stamelou M, Xiromerisiou G, Kosmidis MH, Ntanasi E, Dardiotis E, Hadjigeorgiou GM, Sakka P, Anastasiou CA, Stefanis L, Scarmeas N. (2019) Higher probability of prodromal Parkinson disease is related to lower cognitive performance. Neurology. 92(19):e2261-e2272

33. Kormas C, Zalonis I, Evdokimidis I, Potagas C. (2019) The performance of patients with Parkinson's disease on the Face-Name Associative Memory Examination. Neurol Sci. 2019 Feb;40(2):405-407

34. Kormas C, Zalonis I, Evdokimidis I, Kapaki E, Potagas C.T (2019) The Modality Effect on Delayed Free Recall in Non-demented Patients With Mild Parkinson's Disease Progression. Front Aging Neurosci. 11:189

35. Ravanidis S, Bougea A, Papagiannakis N, Maniati M, Koros C, Simitsi AM, Bozi M, Pachi I, Stamelou M, Paraskevas GP, Kapaki E, Moraitou M, Michelakakis H, Stefanis L, Doxakis E. (2020) Circulating Brain-enriched MicroRNAs for detection and discrimination of idiopathic and genetic Parkinson's disease. Mov Disord. 35(3):457-467

36. Anagnostou E, Karavasilis E, Potiri I, Constantinides V, Efstathopoulos E, Kapaki E, Potagas C. (2020) A Cortical Substrate for Square-Wave Jerks in Progressive Supranuclear Palsy. J Clin Neurol. 2020 Jan;16(1):37-45

37. Koros C, Simitsi AM, Papadimitriou D, Bougea A, Prentakis A, Papagiannakis N, Pachi I, Bozi M, Antonelou R, Angelopoulou E, Beratis I, Papageorgiou SG, Trapali XG, Stamelou M, Stefanis L. (2020)  Serum Uric Acid Level as a Biomarker in Idiopathic and Genetic (p.A53T Alpha-Synuclein Carriers) Parkinson's Disease: Data from the PPMI Study. J Parkinsons Dis. 2020;10(2):481-487

38. Koros C, Simitsi AM, Prentakis A, Papagiannakis N, Bougea A, Pachi I, Papadimitriou D, Beratis I, Papageorgiou SG, Stamelou M, Trapali XG, Stefanis L. (2020) DaTSCAN (123I-FP-CIT SPECT) imaging in early versus mid and late onset Parkinson's disease: Longitudinal data from the PPMI study. Parkinsonism Relat Disord. 77:36-42

39. Emmanouilidou E, Papagiannakis N, Kouloulia S, Galaziou A, Antonellou R, Papadimitriou D, Athanasiadou A, Bozi M, Koros C, Maniati M, Vekrellis K, Ioannou PC, Stefanis L. (2020) Peripheral alpha-synuclein levels in patients with genetic and non-genetic forms of Parkinson's disease. Parkinsonism Relat Disord. 73:35-40

40. Simitsi AM, Koros C, Stamelou M, Papadimitriou D, Leonardos A, Bougea A, Papagiannakis N, Pachi I, Angelopoulou E, Lourentzos K, Bonakis A, Stefanis L. (2021) REM sleep behavior disorder and other sleep abnormalities in p. A53T SNCA mutation carriers. Sleep. 44(5):zsaa248

41. Pachi I, Koros C, Simitsi AM, Papadimitriou D, Bougea A, Prentakis A, Papagiannakis N, Bozi M, Antonelou R, Angelopoulou E, Beratis I, Stamelou M, Trapali XG, Papageorgiou SG, Stefanis L. (2021) Apathy: An underestimated feature in GBA and LRRK2 non-manifesting mutation carriers. Parkinsonism Relat Disord. 2021 Oct;91:1-8

42. Oliveira LMA, Gasser T, Edwards R, Zweckstetter M, Melki R, Stefanis L, Lashuel HA, Sulzer D, Vekrellis K, Halliday GM, Tomlinson JJ, Schlossmacher M, Jensen PH, Schulze-Hentrich J, Riess O, Hirst WD, El-Agnaf O, Mollenhauer B, Lansbury P, Outeiro TF. (2021) Alpha-synuclein research: defining strategic moves in the battle against Parkinson's disease. NPJ Parkinsons Dis. 7(1):65

43. Pachi I, Maraki MI, Giagkou N, Kosmidis MH, Yannakoulia M, Dardiotis E, Hadjigeorgiou G, Sakka P, Ntanasi E, Xiromerisiou G, Stamelou M, Scarmeas N, Stefanis L. (2021) Late life psychotic features in prodromal Parkinson's disease. Parkinsonism Relat Disord. 86:67-73

44. Liu H, Koros C, Strohäker T, Schulte C, Bozi M, Varvaresos S, Ibáñez de Opakua A, Simitsi AM, Bougea A, Voumvourakis K, Maniati M, Papageorgiou SG, Hauser AK, Becker S, Zweckstetter M, Stefanis L, Gasser T. (2021)  A Novel SNCA A30G Mutation Causes Familial Parkinson's Disease. Mov Disord. 36(7):1624-1633

45. Koros C, Simitsi AM, Papagiannakis N, Bougea A, Prentakis A, Papadimitriou D, Pachi I, Antonelou R, Angelopoulou E, Beratis I, Bozi M, Papageorgiou SG, Trapali XG, Stamelou M, Stefanis L. (2021) Serum uric acid level as a putative biomarker in Parkinson's disease patients carrying GBA1 mutations: 2-Year data from the PPMI study. Parkinsonism Relat Disord. 84:1-4

46. Ravanidis S, Bougea A, Karampatsi D, Papagiannakis N, Maniati M, Stefanis L, Doxakis E. (2021) Differentially Expressed Circular RNAs in Peripheral Blood Mononuclear Cells of Patients with Parkinson's Disease. Mov Disord. 36(5):1170-1179

47. Elpidoforou M, Bakalidou D, Drakopoulou M, Kavga A, Chrysovitsanou C, Stefanis L. (2022) Effects of a structured dance program in Parkinson's disease. A Greek pilot study. Complement Ther Clin Pract. 46:101528

48. Avisar H, Guardia-Laguarta C, Surface M, Papagiannakis N, Maniati M, Antonellou R, Papadimitriou D, Koros C, Athanassiadou A, Przedborski S, Lerner B, Stefanis L, Area-Gomez E, Alcalay RN. (2022)  Lipid level alteration in human and cellular models of alpha synuclein mutations. NPJ Parkinsons Dis. 8(1):52

49. Simitsi AM, Koros C, Stamelou M, Beratis I, Efthymiopoulou E, Papadimitriou D, Bougea A, Picillo M, Stanitsa E, Papagiannakis N, Antonelou R, Pachi I, Papageorgiou SG, Barone P, Stefanis L. (2022) Asymptomatic carriers of the p.A53T SNCA mutation: Data from the PPMI study. Parkinsonism Relat Disord. 98:72-74

50. Kormas C, Zalonis I, Evdokimidis I, Kapaki E, Potagas C. (2022) The severity of executive dysfunction among different PD-MCI subtypes. Appl Neuropsychol Adult. 29(4):546-550

51. Petropoulou-Vathi L, Simitsi A, Valkimadi PE, Kedariti M, Dimitrakopoulos L, Koros C, Papadimitriou D, Papadimitriou A, Stefanis L, Alcalay RN, Rideout HJ. (2022) Distinct profiles of LRRK2 activation and Rab GTPase phosphorylation in clinical samples from different PD cohorts. NPJ Parkinsons Dis. 8(1):73

52. Angelopoulou E, Bozi M, Simitsi AM, Koros C, Antonelou R, Papagiannakis N, Maniati M, Poula D, Stamelou M, Vassilatis DK, Michalopoulos I, Geronikolou S, Scarmeas N, Stefanis L. (2022) Clinical differences between early-onset and mid-and-late-onset Parkinson's disease: Data analysis of the Hellenic Biobank of Parkinson's disease. J Neurol Sci. 442:120405

53. Kapsomenakis A, Kasselimis D, Vaniotis E, Bougea A, Koros C, Simitsi AM, Stefanis L, Potagas C. (2023) Frequency of Impulsive-Compulsive Behavior and Associated Psychological Factors in Parkinson's Disease: Lack of Control or Too Much of It? Medicina (Kaunas). 59(11):1942

54. Koros C, Bougea A, Simitsi AM, Papagiannakis N, Angelopoulou E, Pachi I, Antonelou R, Bozi M, Stamelou M, Stefanis L. (2023) The Landscape of Monogenic Parkinson's Disease in Populations of Non-European Ancestry: A Narrative Review. Genes (Basel). 14(11):2097

55. Pachi I, Papadopoulos V, Koros C, Simitsi AM, Bougea A, Bozi M, Papagiannakis N, Soldatos RF, Kolovou D, Pantes G, Scarmeas N, Paraskevas G, Voumvourakis K, Papageorgiou SG, Kollias K, Stefanis N, Stefanis L. (2023) Comprehensive Evaluation of Psychotic Features and Their Clinical Correlates in Early Parkinson's Disease. J Parkinsons Dis. 13(7):1185-1197

56. Pachi I, Papadopoulos V, Xenaki LA, Koros C, Simitsi AM, Bougea A, Bozi M, Papagiannakis N, Soldatos RF, Kolovou D, Pantes G, Scarmeas N, Paraskevas G, Voumvourakis K, Potagas C, Papageorgiou SG, Kollias K, Stefanis N, Stefanis L. (2023) Jumping to conclusions bias, psychosis and impulsivity in early stages of Parkinson's disease. J Neurol. 270(12):5773-5783

57. Koros C, Simitsi AM, Papagiannakis N, Bougea A, Prentakis A, Papadimitriou D, Pachi I, Beratis I, Stanitsa E, Angelopoulou E, Antonelou R, Bregianni M, Lourentzos K, Papageorgiou SG, Bonakis A, Trapali XG, Stamelou M, Stefanis L. (2023) Serum Uric Acid as a Putative Biomarker in Prodromal Parkinson's Disease: Longitudinal Data from the PPMI Study. J Parkinsons Dis. 13(5):811-818

58. Paggou D, Stefanis L, Chronopoulos E, Ghika A, Kyrozis A, Balanika A, Baltas C, Potagas C. (2023) Shoulder Dysfunction in Parkinson Disease: Review of Clinical, Imaging Findings and Contributing Factors. J Musculoskelet Neuronal Interact. 2023 Jun 1;23(2):263-280

59. Outeiro TF, Alcalay RN, Antonini A, Attems J, Bonifati V, Cardoso F, Chesselet MF, Hardy J, Madeo G, McKeith I, Mollenhauer B, Moore DJ, Rascol O, Schlossmacher MG, Soreq H, Stefanis L, Ferreira JJ. (2023) Defining the Riddle in Order to Solve It: There Is More Than One "Parkinson's Disease". Mov Disord. 38(7):1127-1142

60. Koros C, Brockmann K, Simitsi AM, Bougea A, Liu H, Hauser AK, Schulte C, Lerche S, Pachi I, Papagiannakis N, Antonelou R, Zahou A, Wurster I, Efthymiopoulou E, Beratis I, Maniati M, Moraitou M, Michelakakis H, Paraskevas G, Papageorgiou SG, Potagas C, Papadimitriou D, Bozi M, Stamelou M, Gasser T, Stefanis L. (2023) Impact of APOE Genotype on Cognition in Idiopathic and Genetic Forms of Parkinson's Disease. Mov Disord. 38(5):907-909

61. Moraitou M, Sotiroudis G, Papagiannakis N, Ferraz MMJ, Xenakis A, Aerts JMFG, Stefanis L, Michelakakis H. (2023) a-Synuclein and lipids in erythrocytes of Gaucher disease carriers and patients before and after enzyme replacement therapy. PLoS One. 2023 Feb 3;18(2):e0277602

62. Jensen PH, Schlossmacher MG, Stefanis L. (2023) Who Ever Said It Would Be Easy? Reflecting on Two Clinical Trials Targeting α-Synuclein. Mov Disord. 38(3):378-384

63. Papagiannakis N, Liu H, Koros C, Simitsi AM, Stamelou M, Maniati M, Buena-Atienza E, Kartanou C, Karadima G, Makrythanasis P, Vatsellas G, Valente EM, Gasser T, Stefanis L. (2024) Parkin mRNA Expression Levels in Peripheral Blood Mononuclear Cells in Parkin-Related Parkinson's Disease. Mov Disord. 39(4):715-722

64. Burré J, Edwards RH, Halliday G, Lang AE, Lashuel HA, Melki R, Murayama S, Outeiro TF, Papa SM, Stefanis L, Woerman AL, Surmeier DJ, Kalia LV, Takahashi R; MDS Scientific Issues Committee. (2024) Research Priorities on the Role of α-Synuclein in Parkinson's Disease Pathogenesis. Mov Disord. 39(10):1663-1678.

65. Koros C, Simitsi AM, Papagiannakis N, Bougea A, Antonelou R, Pachi I, Sfikas E, Stanitsa E, Angelopoulou E, Constantinides VC, Papageorgiou SG, Potagas C, Stamelou M, Stefanis L. (2024) Precision Dopaminergic Treatment in a Cohort of Parkinson's Disease Patients Carrying Autosomal Recessive Gene Variants: Clinical Cohort Data and a Mini Review. Neurol Int. 16(4):833-844

66. Vekrellis K, Emmanouilidou E, Xilouri M, Stefanis L. (2024) α-Synuclein in Parkinson's Disease: 12 Years Later. Cold Spring Harb Perspect Med. 14(11):a041645

67. Koros C, Bougea A, Alefanti I, Simitsi AM, Papagiannakis N, Pachi I, Sfikas E, Antonelou R, Stefanis L. (2024) A Global Perspective of GBA1-Related Parkinson's Disease: A Narrative Review. Genes (Basel)15(12):1605

68. Alefanti I, Koros C, Tsami V, Simitsi AM, Kartanou C, Papagiannakis N, Bozi M, Antonelou R, Maniati M, Hauser AK, Varvaressos S, Bonakis A, Lourentzos K, Makrythanasis P, Papageorgiou SG, Proukakis C, Potagas C, Gasser T, Koutsis G, Karadima G, Stefanis L. (2025) The novel p.A30G SNCA pathogenic variant in Greek patients with familial and sporadic Parkinson's disease. Eur J Neurol. 32(2):e16562

69. Simitsi AM, Sfikas E, Koros C, Papagiannakis N, Beratis I, Papadimitriou D, Antonellou R, Fragiadaki S, Kontaxopoulou D, Picillo M, Pachi I, Alefanti I, Stamelou M, Barone P, Stefanis L. (2025) Motor and nonmotor features of p.A53T alpha-synuclein PD vs idiopathic PD: longitudinal data from the PPMI study. J Neurol. 272(3):203

70. Dimoula K, Papagiannakis N, Maniati M, Stefanis L, Emmanouilidou E. (2025) Aggregated α-synuclein in erythrocytes as a potential biomarker for idiopathic Parkinson's Disease. Parkinsonism Relat Disord. 133:107321

71. Ravanidis S, Bougea A, Koros C, Simitsi AM, Kokotis P, Stefanis L, Doxakis E. (2025) Plasma miRNA Biomarker Signatures in Parkinsonian Syndromes. Mol Neurobiol. 2025 Apr 4. doi: 10.1007/s12035-025-04890-w

1ST DEPARTMENT OF NEUROLOGY: